Zeneast Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth 16.94%
- Profit Growth 59.01%
- Ebitda 42.37%
- Net Worth 21.20%
- Total Assets 22.66%
About Zeneast Pharmaceuticals
Zeneast Pharmaceuticals Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 June 2015 (Nine years and eight months 26 days old ). Its registered office is in Khorda, Odisha, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 M.
Dusmanta Jena, Anurekha Nayak, Pratap Jena, and Two other members serve as directors at the Company.
Company Details
- Location
Khorda, Odisha, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230OR2015PTC019022
- Company No.
019022
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Who are the key members and board of directors at Zeneast Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dusmanta Jena  | Additional Director | 29-Jun-2015 | Current |
| Anurekha Nayak | Director | 02-Jun-2015 | Current |
| Pratap Jena | Director | 02-Jun-2015 | Current |
| Pradyumna Patra | Director | 02-Jun-2015 | Current |
| Pravat Das | Director | 25-Nov-2022 | Current |
Financial Performance of Zeneast Pharmaceuticals.
Zeneast Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.94% increase. The company also saw a substantial improvement in profitability, with a 59.01% increase in profit. The company's net worth Soared by an impressive increase of 21.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeneast Pharmaceuticals?
In 2023, Zeneast Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Dena Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Feb 2016 | Dena Bank | ₹1.00 M | Open |
How Many Employees Work at Zeneast Pharmaceuticals?
Zeneast Pharmaceuticals has a workforce of 5 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeneast Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeneast Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.